Indicators
Indicators
Value
Direction
MACD(12,26,9)
1.518
Buy
RSI(14)
61.883
Neutral
STOCH(KDJ)(9,3,3)
67.302
Neutral
ATR(14)
11.036
High Vlolatility
CCI(14)
76.168
Neutral
Williams %R
20.151
Buy
TRIX(12,20)
0.251
Sell
StochRSI(14)
100.000
Buy
Vertex Pharmaceuticals Inc
VRTX455.710USD
+3.670+0.81%
Close 12/15, 16:00（ET）Quotes delayed by 15 min
115.73BMarket Cap
31.85P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Vertex Pharmaceuticals Inc
Currency: USD Updated: 2025-12-12Key Insights
Vertex Pharmaceuticals Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 7/159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 489.09.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Vertex Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
33
analysts
Buy
Current Rating
489.093
Target Price
+10.64%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Vertex Pharmaceuticals Inc Highlights
StrengthsRisks
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 23.40% year-on-year.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Overvalued
The company’s latest PE is 31.59, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 249.27M shares, decreasing 0.85% quarter-over-quarter.
Held by Ken Fisher
Star Investor Ken Fisher holds 25.96K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.81.
Financial Health
Currency: USD Updated: 2025-12-12The current financial score of Vertex Pharmaceuticals Inc is 9.08, ranking 19/159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 3.08B, representing a year-over-year increase of 10.99%, while its net profit experienced a year-over-year increase of 3.59%.
Score
Financials
9.01
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.56
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
7.85
Vertex Pharmaceuticals Inc's Company Valuation
Currency: USD Updated: 2025-12-12The current valuation score of Vertex Pharmaceuticals Inc is 6.13, ranking 133/159 in the Pharmaceuticals industry. Its current P/E ratio is 31.59, which is 7.46% below the recent high of 33.95 and 982.63% above the recent low of -278.85.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 7/159
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-12The current earnings forecast score of Vertex Pharmaceuticals Inc is 7.58, ranking 101/159 in the Pharmaceuticals industry. The average price target for Vertex Pharmaceuticals Inc is 492.50, with a high of 604.00 and a low of 330.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
33
analysts
Buy
Current Rating
489.093
Target Price
+10.64%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
171
Total
6
Median
8
Average
Company name
Ratings
Analysts
Vertex Pharmaceuticals Inc
VRTX
33
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Eli Lilly and Co
LLY
33
AbbVie Inc
ABBV
32
Gilead Sciences Inc
GILD
31
1
2
3
...
34
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-12The current price momentum score of Vertex Pharmaceuticals Inc is 9.17, ranking 34/159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 471.08 and the support level at 425.76, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
447.066
Buy
MA10
448.649
Buy
MA20
438.567
Buy
MA50
426.979
Buy
MA100
413.834
Buy
MA200
441.817
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-12The current institutional shareholding score of Vertex Pharmaceuticals Inc is 10.00, ranking 1/159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 98.24%, representing a quarter-over-quarter decrease of 0.33%. The largest institutional shareholder is The Vanguard, holding a total of 24.10M shares, representing 9.50% of shares outstanding, with 4.33% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Capital World Investors
Capital Research Global Investors
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
Geode Capital Management, L.L.C.
Invesco Capital Management (QQQ Trust)
Wellington Management Company, LLP
Capital International Investors
AllianceBernstein L.P.
1
2
Risk Assessment
Currency: USD Updated: 2025-12-12The current risk assessment score of Vertex Pharmaceuticals Inc is 9.81, ranking 3/159 in the Pharmaceuticals industry. The company's beta value is 0.32. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.31
VaR
+2.34%
240-Day Maximum Drawdown
+28.66%
240-Day Volatility
+33.33%
Return
Best Daily Return
60 days
+6.92%
120 days
+6.92%
5 years
+13.23%
Worst Daily Return
60 days
-3.33%
120 days
-20.60%
5 years
-20.60%
Sharpe Ratio
60 days
+2.75
120 days
+0.27
5 years
+0.71
Risk Assessment
Maximum Drawdown
240 days
+28.66%
3 years
+29.07%
5 years
+29.07%
Return-to-Drawdown Ratio
240 days
+0.49
3 years
+0.50
5 years
+0.78
Skewness
240 days
-4.00
3 years
-2.21
5 years
-1.39
Volatility
Realised Volatility
240 days
+33.33%
5 years
+28.22%
Standardised True Range
240 days
+2.53%
5 years
+1.77%
Downside Risk-Adjusted Return
120 days
+24.78%
240 days
+24.78%
Maximum Daily Upside Volatility
60 days
+19.51%
Maximum Daily Downside Volatility
60 days
+16.92%
Liquidity
Average Turnover Rate
60 days
+0.65%
120 days
+0.67%
5 years
--
Turnover Deviation
20 days
+81.48%
60 days
+18.85%
120 days
+21.83%
Peer Comparison
Pharmaceuticals
Vertex Pharmaceuticals Inc
VRTX
8.52 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.88 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Prestige Consumer Healthcare Inc
PBH
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Collegium Pharmaceutical Inc
COLL
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
8.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Vertex Pharmaceuticals Inc?
The TradingKey Stock Score provides a comprehensive assessment of Vertex Pharmaceuticals Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Vertex Pharmaceuticals Inc’s performance and outlook.
How do we generate the financial health score of Vertex Pharmaceuticals Inc?
To generate the financial health score of Vertex Pharmaceuticals Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Vertex Pharmaceuticals Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Vertex Pharmaceuticals Inc.
How do we generate the company valuation score of Vertex Pharmaceuticals Inc?
To generate the company valuation score of Vertex Pharmaceuticals Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Vertex Pharmaceuticals Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Vertex Pharmaceuticals Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Vertex Pharmaceuticals Inc.
How do we generate the earnings forecast score of Vertex Pharmaceuticals Inc?
To calculate the earnings forecast score of Vertex Pharmaceuticals Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Vertex Pharmaceuticals Inc’s future.
How do we generate the price momentum score of Vertex Pharmaceuticals Inc?
When generating the price momentum score for Vertex Pharmaceuticals Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Vertex Pharmaceuticals Inc’s prices. A higher score indicates a more stable short-term price trend for Vertex Pharmaceuticals Inc.
How do we generate the institutional confidence score of Vertex Pharmaceuticals Inc?
To generate the institutional confidence score of Vertex Pharmaceuticals Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Vertex Pharmaceuticals Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Vertex Pharmaceuticals Inc.
How do we generate the risk management score of Vertex Pharmaceuticals Inc?
To assess the risk management score of Vertex Pharmaceuticals Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Vertex Pharmaceuticals Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Vertex Pharmaceuticals Inc.
